Emavusertib hydrochloride is under clinical development by Curis and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Emavusertib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Emavusertib hydrochloride overview
Emavusertib hydrochloride is under development for the treatment of diffuse large B cell lymphomas, relapsed or refractory follicular lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia., mantle cell lymphoma, primary CNS lymphoma, secondary CNS lymphoma non-Hodgkin lymphomas such as Waldenstrom macroglobulinemia and marginal zone lymphoma, hematologic malignancies, gastric cancer, pancreatic ductal adenocarcinoma, metastatic melanoma, esophageal cancer and adenocarcinoma of the gastroesophageal junction, non-Hodgkin lymphomas such as myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) and chronic myelocytic leukemia (CML, chronic myeloid leukemia). It is a small molecule administered orally. The drug candidate targets interleukin-1 receptor-associated kinase-4 (IRAK-4) and FLT3 (FMS like tyrosine kinase 3). It was also under development for the treatment of rheumatoid arthritis and relapsed or refractory acute myelocytic leukemia.
Curis is a biotechnology company that focuses on developing and commercializing novel drug candidates for treating cancers with substantial unmet medical need. The company’s lead product Erivedge has been developed in collaboration with F. Hoffmann-La Roche Ltd and Genentech, which is commercialized for the treatment of advanced basal cell carcinoma (BCC). The product is approved for use in patients with advanced BCC in the US, European Union (EU), Australia and several other countries.
For a complete picture of Emavusertib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.